The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
Four-year data: On Wednesday, July 30, as part of the "Developing Topics Session: Innovative Therapeutic Approaches" (8:00 – 8:45 AM EDT), initial four-year findings will be presented on lecanemab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results